# CytomX Therapeutics, Inc.: financial statements, quarterly

CTMX · Nasdaq · CIK 1501989 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ctmx.md) · [Financials](/companies/ctmx/financials.md) · [Filings](/companies/ctmx/filings.md) · [Insiders](/companies/ctmx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ctmx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [26.4](/filings/0000950170-24-123249.md) | [26.6 d](/filings/0000950170-25-034575.md) | [41.5](/filings/0000950170-25-068511.md) | [25.1](/filings/0000950170-25-104991.md) | [33.4](/filings/0001193125-25-269477.md) | [38.1 d](/filings/0001193125-26-107146.md) | [50.9](/filings/0001193125-26-211868.md) | [18.7](/filings/0001193125-26-337950.md) | [6.0](/filings/0001193125-25-269477.md) | [0.7 d](/filings/0001193125-26-107146.md) | [10.3](/filings/0001193125-26-211868.md) | [1.4](/filings/0001193125-26-337950.md) |
| Research and development | $m | [16.4](/filings/0000950170-24-123249.md) | [19.4 d](/filings/0000950170-25-034575.md) | [22.1](/filings/0000950170-25-068511.md) | [25.2](/filings/0000950170-25-104991.md) | [21.4](/filings/0001193125-25-269477.md) | [14.8 d](/filings/0001193125-26-107146.md) | [18.9](/filings/0001193125-26-211868.md) | [13.3](/filings/0001193125-26-337950.md) | [15.3](/filings/0001193125-25-269477.md) | [21.2 d](/filings/0001193125-26-107146.md) | [19.2](/filings/0001193125-26-211868.md) | [17.6](/filings/0001193125-26-337950.md) |
| Operating income | $m | [3.1](/filings/0000950170-24-123249.md) | [(0.6) d](/filings/0000950170-25-034575.md) | [11.7](/filings/0000950170-25-068511.md) | [(8.5)](/filings/0000950170-25-104991.md) | [4.1](/filings/0001193125-25-269477.md) | [17.7 d](/filings/0001193125-26-107146.md) | [22.6](/filings/0001193125-26-211868.md) | [(1.3)](/filings/0001193125-26-337950.md) | [(15.8)](/filings/0001193125-25-269477.md) | [(27.9) d](/filings/0001193125-26-107146.md) | [(19.7)](/filings/0001193125-26-211868.md) | [(23.8)](/filings/0001193125-26-337950.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [2.8](/filings/0000950170-24-123249.md) | [1.1 d](/filings/0000950170-25-034575.md) | [0.0](/filings/0000950170-25-068511.md) | [0.1](/filings/0000950170-25-104991.md) | [0.1](/filings/0001193125-25-269477.md) | [0.1 d](/filings/0001193125-26-107146.md) | [0.1](/filings/0001193125-26-211868.md) | [0.1](/filings/0001193125-26-337950.md) | [0.1](/filings/0001193125-25-269477.md) | [0.1 d](/filings/0001193125-26-107146.md) | [0.1](/filings/0001193125-26-211868.md) | [0.1](/filings/0001193125-26-337950.md) |
| Net income | $m | [3.0](/filings/0000950170-24-123249.md) | [0.8 d](/filings/0000950170-25-034575.md) | [13.8](/filings/0001193125-25-269477.md) | [(6.5)](/filings/0001193125-25-269477.md) | [5.7](/filings/0001193125-25-269477.md) | [18.9 d](/filings/0001193125-26-107146.md) | [23.5](/filings/0001193125-26-337950.md) | [(0.2)](/filings/0001193125-26-337950.md) | [(14.2)](/filings/0001193125-25-269477.md) | [(26.5) d](/filings/0001193125-26-107146.md) | [(18.2)](/filings/0001193125-26-337950.md) | [(20.7)](/filings/0001193125-26-337950.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [26.0](/filings/0000950170-23-060201.md) | [17.2](/filings/0000950170-25-034575.md) | [36.2](/filings/0000950170-24-055588.md) | [43.2](/filings/0000950170-24-093865.md) | [40.6](/filings/0000950170-24-123249.md) | [38.1](/filings/0001193125-26-107146.md) | [47.6](/filings/0000950170-25-068511.md) | [49.0](/filings/0000950170-25-104991.md) | [34.2](/filings/0001193125-25-269477.md) | [12.7](/filings/0001193125-26-337950.md) | [28.8](/filings/0001193125-26-211868.md) | [17.2](/filings/0001193125-26-337950.md) |
| Current assets | $m | [201](/filings/0000950170-23-060201.md) | [183](/filings/0000950170-25-034575.md) | [167](/filings/0000950170-24-055588.md) | [143](/filings/0000950170-24-093865.md) | [124](/filings/0000950170-24-123249.md) | [107](/filings/0001193125-26-107146.md) | [86.6](/filings/0000950170-25-068511.md) | [165](/filings/0000950170-25-104991.md) | [149](/filings/0001193125-25-269477.md) | [144](/filings/0001193125-26-337950.md) | [353](/filings/0001193125-26-211868.md) | [373](/filings/0001193125-26-337950.md) |
| Total assets | $m | [221](/filings/0000950170-23-060201.md) | [202](/filings/0000950170-25-034575.md) | [185](/filings/0000950170-24-055588.md) | [159](/filings/0000950170-24-093865.md) | [139](/filings/0000950170-24-123249.md) | [121](/filings/0001193125-26-107146.md) | [98.5](/filings/0000950170-25-068511.md) | [175](/filings/0000950170-25-104991.md) | [158](/filings/0001193125-25-269477.md) | [152](/filings/0001193125-26-337950.md) | [359](/filings/0001193125-26-211868.md) | [381](/filings/0001193125-26-337950.md) |
| Current liabilities | $m | [147](/filings/0000950170-23-060201.md) | [156](/filings/0000950170-25-034575.md) | [145](/filings/0000950170-24-055588.md) | [143](/filings/0000950170-24-093865.md) | [119](/filings/0000950170-24-123249.md) | [85.8](/filings/0001193125-26-107146.md) | [50.2](/filings/0000950170-25-068511.md) | [39.2](/filings/0000950170-25-104991.md) | [41.0](/filings/0001193125-25-269477.md) | [46.6](/filings/0001193125-26-337950.md) | [34.0](/filings/0001193125-26-211868.md) | [39.9](/filings/0001193125-26-337950.md) |
| Total liabilities | $m | [272](/filings/0000950170-23-060201.md) | [249](/filings/0000950170-25-034575.md) | [216](/filings/0000950170-24-055588.md) | [190](/filings/0000950170-24-093865.md) | [162](/filings/0000950170-24-123249.md) | [121](/filings/0001193125-26-107146.md) | [73.4](/filings/0000950170-25-068511.md) | [55.1](/filings/0000950170-25-104991.md) | [50.9](/filings/0001193125-25-269477.md) | [52.6](/filings/0001193125-26-337950.md) | [39.4](/filings/0001193125-26-211868.md) | [79.2](/filings/0001193125-26-337950.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(51.2)](/filings/0000950170-24-123249.md) | [(47.4)](/filings/0001193125-26-107146.md) | [(31.7)](/filings/0001193125-25-269477.md) | [(31.2)](/filings/0001193125-25-269477.md) | [(23.5)](/filings/0001193125-25-269477.md) | [(0.5)](/filings/0001193125-26-337950.md) | [25.0](/filings/0001193125-26-337950.md) | [120](/filings/0001193125-26-337950.md) | [107](/filings/0001193125-25-269477.md) | [99.0](/filings/0001193125-26-337950.md) | [320](/filings/0001193125-26-337950.md) | [302](/filings/0001193125-26-337950.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(18.2) d](/filings/0000950170-24-123249.md) | [(22.0) d](/filings/0000950170-25-034575.md) | [(26.0)](/filings/0000950170-25-068511.md) | [(19.5) d](/filings/0000950170-25-104991.md) | [(20.7) d](/filings/0001193125-25-269477.md) | [(19.9) d](/filings/0001193125-26-107146.md) | [(21.0)](/filings/0001193125-26-211868.md) | [(15.8) d](/filings/0001193125-26-337950.md) | [(15.5) d](/filings/0001193125-25-269477.md) | [(23.2) d](/filings/0001193125-26-107146.md) | [(25.5)](/filings/0001193125-26-211868.md) | [(18.1) d](/filings/0001193125-26-337950.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-123249.md) | [0.3 d](/filings/0000950170-25-034575.md) | [0.1](/filings/0000950170-25-068511.md) | [0.1 d](/filings/0000950170-25-104991.md) | [0.0 d](/filings/0001193125-25-269477.md) | [0.1 d](/filings/0001193125-26-107146.md) | [0.1](/filings/0001193125-26-211868.md) | [0.0 d](/filings/0001193125-26-337950.md) | [(0.1) d](/filings/0001193125-25-269477.md) | [0.2 d](/filings/0001193125-26-107146.md) | [0.0](/filings/0001193125-26-211868.md) | [0.0 d](/filings/0001193125-26-337950.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [65.9](/filings/0000950170-23-060201.md) | [66.2](/filings/0000950170-24-055588.md) | [66.5](/filings/0000950170-24-093865.md) | [81.0](/filings/0000950170-24-123249.md) | [82.6](/filings/0000950170-25-068511.md) | [84.9](/filings/0000950170-25-104991.md) | [85.2](/filings/0001193125-25-269477.md) | [87.2](/filings/0001193125-26-211868.md) | [129](/filings/0001193125-26-337950.md) | [165](/filings/0001193125-25-269477.md) | [177](/filings/0001193125-26-211868.md) | [219](/filings/0001193125-26-337950.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 217,899,284 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-337950.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.